US Stock MarketDetailed Quotes
CALT Calliditas Therapeutics
- 38.190
- +0.040+0.10%
Close Jul 26 16:00 ET
- 37.000
- -1.190-3.12%
Post 20:01 ET
1.02BMarket Cap-21134P/E (TTM)
38.190High37.810Low3.64KVolume38.140Open38.150Pre Close138.10KTurnover0.02%Turnover RatioLossP/E (Static)26.84MShares41.90052wk High92.47P/B611.86MFloat Cap15.25052wk Low--Dividend TTM16.02MShs Float41.900Historical High--Div YieldTTM1.00%Amplitude10.820Historical Low37.959Avg Price1Lot Size
Calliditas Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 54.42%295.48M | 50.32%1.21B | 5.25%451.56M | 13.28%294.59M | 320.60%269.38M | 284.75%191.35M | 250.07%802.88M | 1,276.02%429.04M | 31.23%260.06M | 64.05M |
| Operating revenue | 54.42%295.48M | 50.32%1.21B | 5.25%451.56M | 13.28%294.59M | 320.60%269.38M | 284.75%191.35M | 250.07%802.88M | 1,276.02%429.04M | 31.23%260.06M | --64.05M |
| Cost of revenue | 55.21%14.01M | 297.76%60.46M | 183.02%22.3M | 245.23%14.92M | 495.97%14.21M | 1,370.36%9.03M | 15.2M | 7.88M | 4.32M | 2.39M |
| Gross profit | 54.38%281.47M | 45.54%1.15B | 1.92%429.26M | 9.36%279.67M | 313.82%255.17M | 271.18%182.32M | 243.44%787.68M | 1,250.75%421.16M | 29.05%255.73M | 61.66M |
| Operating expense | 33.91%485.3M | 31.12%1.56B | 15.94%423.86M | 50.45%439.24M | 21.67%330.34M | 40.74%362.4M | 58.69%1.19B | 47.88%365.59M | 53.41%291.96M | 70.33%271.51M |
| Selling and administrative expenses | 42.70%342.17M | 36.93%1.06B | 7.42%293.17M | 38.49%259.17M | 56.01%268.62M | 68.34%239.77M | 98.51%774.66M | 79.89%272.92M | 96.22%187.14M | 104.07%172.18M |
| -Selling and marketing expense | 43.61%240.15M | 41.26%727.74M | 3.47%198.54M | 46.81%170.5M | 69.04%191.47M | 78.09%167.22M | 186.85%515.19M | 171.65%191.89M | 272.57%116.14M | 94.07%113.27M |
| -General and administrative expense | 40.62%102.02M | 28.34%332.99M | 16.78%94.62M | 24.88%88.67M | 30.97%77.15M | 49.48%72.55M | 23.19%259.47M | -0.05%81.03M | 10.60%71M | 126.53%58.91M |
| Research and development costs | 18.92%150.61M | 21.09%502.22M | 4.34%106.68M | 74.87%179.91M | -7.59%88.99M | 11.74%126.65M | 16.02%414.75M | 1.94%102.24M | 11.70%102.88M | 28.35%96.29M |
| Other operating expenses | -85.82%-7.48M | -148.43%-7.11M | 351.20%24.02M | -91.42%167K | -997.53%-27.27M | -334.95%-4.03M | ---2.86M | ---9.56M | -31.50%1.95M | 43,300.00%3.04M |
| Operating profit | -13.19%-203.83M | -2.65%-409.42M | -90.28%5.4M | -340.48%-159.57M | 64.18%-75.17M | 13.58%-180.08M | 23.05%-398.87M | 125.72%55.57M | -561.08%-36.23M | -31.65%-209.85M |
| Net non-operating interest income expense | -55.66%-43.5M | -149.89%-85.25M | 17.02%-57.31M | -122.25%-4.51M | -74.59%4.51M | -810.82%-27.94M | -272.81%-34.12M | -316.89%-69.07M | 1,574.11%20.27M | 405.37%17.75M |
| Non-operating interest income | ---- | 718.89%29.1M | ---- | ---- | ---- | ---- | 3,383.33%3.55M | ---- | ---- | ---- |
| Non-operating interest expense | 55.66%43.5M | 123.20%73.2M | ---- | ---- | ---- | --27.94M | 361.38%32.8M | ---- | ---- | ---- |
| Total other finance cost | ---- | 744.28%41.15M | -66.84%13.21M | 122.25%4.51M | 74.59%-4.51M | ---- | 127.23%4.87M | 316.53%39.83M | -1,574.11%-20.27M | -405.37%-17.75M |
| Other net income (expense) | 59.77%37.66M | 66.57%23.57M | ||||||||
| Gain on sale of security | ---- | -54.75%17.88M | ---- | ---- | ---- | ---- | 112.69%39.51M | ---- | ---- | ---- |
| Special income (charges) | ---- | 224.06%19.78M | ---- | ---- | ---- | ---- | -260.09%-15.94M | ---- | ---- | ---- |
| -Less：Restructuring and merger&acquisition | ---- | -218.15%-18.84M | ---- | ---- | ---- | ---- | 256.62%15.94M | ---- | ---- | ---- |
| -Gain on sale of property,plant,equipment | ---- | --941K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Income before tax | -18.89%-247.32M | -11.63%-457.02M | -241.64%-14.26M | -928.21%-164.08M | 63.22%-70.66M | 1.62%-208.02M | 20.25%-409.42M | 104.61%10.07M | -346.27%-15.96M | -16.27%-192.09M |
| Income tax | 94.32%-1.16M | 221.57%9.17M | -70.09%4.11M | 162.44%4.28M | 6,175.52%21.27M | -367.15%-20.49M | 174.32%2.85M | 6,808.04%13.75M | -2,233.33%-6.85M | 132.16%339K |
| Net income | -31.27%-246.16M | -13.08%-466.19M | -398.99%-18.37M | -1,747.84%-168.36M | 52.22%-91.93M | 9.43%-187.53M | 19.09%-412.27M | 98.32%-3.68M | -247.93%-9.11M | -17.22%-192.43M |
| Net income continuous Operations | -31.27%-246.16M | -13.08%-466.19M | -399.02%-18.37M | -1,748.06%-168.36M | 52.22%-91.93M | 9.43%-187.53M | 19.09%-412.27M | 98.32%-3.68M | -247.91%-9.11M | -17.22%-192.43M |
| Minority interest income | 0 | 0 | ||||||||
| Net income attributable to the parent company | -31.27%-246.16M | -13.08%-466.19M | -398.99%-18.37M | -1,747.84%-168.36M | 52.22%-91.93M | 9.43%-187.53M | 17.59%-412.27M | 98.32%-3.68M | -186.17%-9.11M | -19.65%-192.43M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -31.27%-246.16M | -13.08%-466.19M | -398.99%-18.37M | -1,747.84%-168.36M | 52.22%-91.93M | 9.43%-187.53M | 17.59%-412.27M | 98.32%-3.68M | -186.17%-9.11M | -19.65%-192.43M |
| Basic earnings per share | -31.52%-9.18 | -11.70%-17.38 | -466.67%-0.68 | -1,747.06%-6.28 | 52.76%-3.42 | 11.65%-6.98 | 20.93%-15.56 | 98.57%-0.12 | -180.95%-0.34 | -12.42%-7.24 |
| Diluted earnings per share | -31.52%-9.18 | -11.70%-17.38 | -466.67%-0.68 | -1,747.06%-6.28 | 52.76%-3.42 | 11.65%-6.98 | 20.93%-15.56 | 98.57%-0.12 | -180.95%-0.34 | -12.42%-7.24 |
| Dividend per share | ||||||||||
| Currency Unit | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg